Dr. Gainor on the Evolving Lung Cancer Armamentarium

Justin F. Gainor, MD, director of Targeted Immunotherapy, Massachusetts General Hospital, and assistant professor of medicine, Harvard Medical School, discusses the evolving lung cancer armamentarium.

Following the recognition that lung cancer is a heterogeneous disease, the field has evolved dramatically, says Gainor. The disease is now defined by different genetic alterations as well as oncogenic drivers.

Notably, in recent years, several targeted therapies have received regulatory approval for 7 molecular alterations in this space.

Ultimately, these approvals created a rich environment for targeted therapies and underscored the importance of genetic profiling, especially when it comes to administering optimal therapies to patients with newly diagnosed lung cancer, Gainor concludes.